Anne Louise van Els

Anne Louise van Els

Auto-generated profile, based on publicly available information

Anne Louise van Els

Amsterdam Institute for Infection and Immunity, Infectious diseases, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2022 in Eurosurveillance
Verified
Journal Article
Open access
AFA Marceline Tutu van Furth
A Marceline Tutu van Furth
MKMartijn van der Kuip
Martijn van der Kuip
AEAnne L van Els
Anne L van Els
LFLydia Cr Fievez
Lydia Cr Fievez
GRGini Gc van Rijckevorsel
Gini Gc van Rijckevorsel
MWMatthijs Ra Welkers
Matthijs Ra Welkers
Since May 2022, an international monkeypox (MPX) outbreak has been ongoing in more than 50 countries. While most cases are men who have sex with men, transmission is not restricted to this population. In this report, we describe the case of a male child younger than 10 years with MPX in the Netherlands. Despite thorough source tracing, a likely source of infection has not been identified. No secondary cases were identified in close contacts.

30 November 2017 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
IKIrene L. M. Klaassen
Irene L. M. Klaassen
AEAnne L. van Els
Anne L. van Els
MWMarianne D. van de Wetering
Marianne D. van de Wetering
COCornelia Heleen Van Ommen
Cornelia Heleen Van Ommen
Venous thromboembolism (VTE) is a serious complication in paediatric oncology patients. To identify the incidence, risk factors and recurrence rate of VTE in paediatric oncology patients, an observational, retrospective cohort study of all consecutive children (≤18 years) with malignancies, treated at the Emma Children's Hospital Academic Medical Centre between January 1989 and December 2013, was done. A matched case–control study in children with lymphomas was performed, to identify thrombotic risk factors. Cumulative recurrence-free survival after first VTE was estimated by the Kaplan–Meier method. Of the 2,183 children included (male: female = 1.4:1.0; median age, 6.6 years) with cancer, 78 patients developed VTE (3.6%; 95% confidence interval [CI], 2.8–4.4). The incidence increased from 0.8% (4/478, 95% CI, 0.0–1.6) between 1989 and 1993 to 10.4% (44/423, 95% CI, 7.6–13.4) between 2009 and 2013. Independent risk factors for VTE were age ≥ 12 years, acute lymphoblastic leukaemia (ALL) and lymphoma. The case–control study in lymphoma patients showed a trend for increased VTE incidence in stage IV lymphoma. Twelve (15.4%) patients developed recurrent thrombosis, 7 patients while on therapeutic or prophylactic anticoagulation. The cumulative recurrence-free survival after first VTE was 88.5, 87.1 and 80.6% after 1, 5 and 10 years, respectively. In conclusion, we demonstrated an increasing incidence of VTE in children with malignancies, with age ≥ 12 years, ALL and lymphoma as independent risk factors. The elevated recurrence rate underlines the importance of full anticoagulant therapy and might warrant prophylactic anticoagulation after first VTE during cancer treatment.

26 February 2017 in Acta Paediatrica
Verified
Journal Article
Closed access
PDF file
AEAnne L. van Els
Anne L. van Els
JDJ Joris van Driel
J Joris van Driel
CKCm Frank Kneepkens
Cm Frank Kneepkens
TMTim G. J. de Meij
Tim G. J. de Meij

1 December 2020 in Pediatrics & Neonatology
Verified
Journal Article
Open access
AEAnne Louise van Els
Anne Louise van Els
JIJoël Israëls
Joël Israëls
MHMarianne Alice van Houten
Marianne Alice van Houten
TMTimotheüs Gualtherus Jacob de Meij
Timotheüs Gualtherus Jacob de Meij

1 January 2014
Verified
Journal Article
Closed access
AEAnne L Van Els
Anne L Van Els
ADA J Noud Drewes
A J Noud Drewes